252 Participants Needed

PF-07275315 for Asthma

Recruiting at 6 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Pfizer
Must be taking: ICS-LABA
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected.This study is seeking participants who:* Are 18 to 70 years old* Have had moderate-to-severe asthma for at least 12 months that is not well controlled* Have been taking their regular maintenance treatment(s) for asthma over the last 12 monthsAll participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.Participants will be involved in this study for about 9.5 months. During this time, they will have 10 visits at the study clinic.

Research Team

PC

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

This trial is for people aged 18-70 with moderate-to-severe asthma that's been active for at least a year and isn't well-managed despite regular treatment. Participants will be involved in the study for about 9.5 months, with 10 clinic visits.

Inclusion Criteria

ACQ-5 score of ≥1.5 at screening visit and prior to randomization
Body mass index between 18 40 kg/m2 at screening
I meet the specific criteria for asthma.
See 5 more

Exclusion Criteria

Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
History of anaphylaxis to antibody therapeutic or to PF-07275315 or to the excipients of the formulated drug products
I have not had bronchial thermoplasty in the last 2 years.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive PF-07275315 or placebo as multiple shots in the clinic over the course of 12 weeks

12 weeks
10 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

20 weeks

Treatment Details

Interventions

  • PF-07275315
Trial Overview The trial tests PF-07275315, a potential new asthma medication, against a placebo (a shot without any medicine). Over 12 weeks, participants receive multiple shots to determine if PF-07275315 is safe and effective.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Arm CExperimental Treatment1 Intervention
PF-07275315
Group II: Treatment Arm BExperimental Treatment1 Intervention
PF-07275315
Group III: Treatment Arm AExperimental Treatment1 Intervention
PF-07275315
Group IV: Treatment Arm DPlacebo Group1 Intervention
Placebo

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security